NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced its financial results for the quarter ended June 30, 2008. For the second quarter of 2008, the Company reported adjusted net income of $27.1 million or earnings of $0.31 per diluted share, compared with net income of $31.9 million or earnings of $0.36 per diluted share for the second quarter of 2007.
